A landmark network meta- **Developing Article Components** I'm now diving deep into the content, focusing on fleshing out each section. The Highlight section's first drafts are complete. I'm incorporating the study's key findings on drug efficacy rankings, and the unique safety profile of Xanomeline-Trospium. I'm simultaneously drafting the study design, and drafting the background section, and I am ensuring a clear comparison of the two, while keeping the technical details accurate. analysis of 438 RCTs reveals significant efficacy differences among antipsychotics and highlights the unique clinical profile of the first-in-class muscarinic agonist, xanomeline-trospium, relative to traditional antidopaminergic agents.